(Q37441525)

English

Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies (English)

1 reference

Europe PubMed Central

20 August 2017

phase I clinical trial

0 references

Razelle Kurzrock

17

object named as

Razelle Kurzrock

1 reference

Europe PubMed Central

20 August 2017

9

object named as

Aung Naing

1 reference

Europe PubMed Central

20 August 2017

author name string

David S Hong

1

1 reference

Europe PubMed Central

20 August 2017

Said M Sebti

2

1 reference

Europe PubMed Central

20 August 2017

Robert A Newman

3

1 reference

Europe PubMed Central

20 August 2017

Michelle A Blaskovich

4

1 reference

Europe PubMed Central

20 August 2017

Lei Ye

5

1 reference

Europe PubMed Central

20 August 2017

Robert F Gagel

6

1 reference

Europe PubMed Central

20 August 2017

Stacy Moulder

7

1 reference

Europe PubMed Central

20 August 2017

Jennifer J Wheler

8

1 reference

Europe PubMed Central

20 August 2017

Nizar M Tannir

10

1 reference

Europe PubMed Central

20 August 2017

Chaan S Ng

11

1 reference

Europe PubMed Central

20 August 2017

Steven I Sherman

12

1 reference

Europe PubMed Central

20 August 2017

Adel K El Naggar

13

1 reference

Europe PubMed Central

20 August 2017

Rabia Khan

14

1 reference

Europe PubMed Central

20 August 2017

Jon Trent

15

1 reference

Europe PubMed Central

20 August 2017

John J Wright

16

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

10 November 2009

1 reference

Europe PubMed Central

20 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

20 August 2017

15

1 reference

Europe PubMed Central

20 August 2017

22

1 reference

Europe PubMed Central

20 August 2017

7061-7068

1 reference

Europe PubMed Central

20 August 2017

Phase II trial of sorafenib in metastatic thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

23 August 2017

Sorafenib for the treatment of unresectable hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

23 August 2017

Phase II trial of sorafenib in advanced thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

23 August 2017

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

23 August 2017

Development of farnesyl transferase inhibitors: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

23 August 2017

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

23 August 2017

Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

23 August 2017

Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

23 August 2017

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

23 August 2017

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

23 August 2017

Farnesyl transferase inhibitors in myeloid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

23 August 2017

Discovery of a novel Raf kinase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

23 August 2017

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

14 September 2017

Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

14 September 2017

Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

2 September 2018

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

2 September 2018

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

2 September 2018

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

2 September 2018

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

2 September 2018

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

3 December 2018

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2784003

3 December 2018

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19903778

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measuring response in solid tumors: unidimensional versus bidimensional measurement

1 reference

https://pubmed.ncbi.nlm.nih.gov/19903778

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19903778

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biomarkers in gastrointestinal stromal tumor: should we equate blood-based pharmacodynamics with tumor biology and clinical outcomes?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19903778

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-09-1241

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37441525&oldid=1749490579"